Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatectomy | 18 | 2013 | 962 | 1.690 |
Why?
|
| Nephrectomy | 11 | 2012 | 779 | 1.400 |
Why?
|
| Prostate-Specific Antigen | 11 | 2013 | 993 | 1.140 |
Why?
|
| Prostatic Neoplasms | 17 | 2013 | 5767 | 0.980 |
Why?
|
| Prostate | 7 | 2018 | 1088 | 0.960 |
Why?
|
| Lymph Node Excision | 9 | 2015 | 1959 | 0.860 |
Why?
|
| Kidney Neoplasms | 12 | 2020 | 3022 | 0.760 |
Why?
|
| Urinary Bladder Neoplasms | 15 | 2021 | 2341 | 0.710 |
Why?
|
| Carcinoma, Transitional Cell | 10 | 2019 | 962 | 0.680 |
Why?
|
| Laparoscopy | 9 | 2012 | 1225 | 0.630 |
Why?
|
| Cystectomy | 10 | 2018 | 623 | 0.480 |
Why?
|
| Nomograms | 2 | 2015 | 313 | 0.440 |
Why?
|
| Lymph Nodes | 3 | 2012 | 2967 | 0.420 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2010 | 84 | 0.380 |
Why?
|
| Urothelium | 6 | 2021 | 254 | 0.380 |
Why?
|
| Warm Ischemia | 2 | 2012 | 22 | 0.370 |
Why?
|
| Mitomycin | 2 | 2021 | 208 | 0.360 |
Why?
|
| Ureteral Neoplasms | 4 | 2019 | 228 | 0.330 |
Why?
|
| Ileostomy | 1 | 2009 | 46 | 0.330 |
Why?
|
| Drainage | 1 | 2011 | 416 | 0.330 |
Why?
|
| Granular Cell Tumor | 1 | 2008 | 22 | 0.320 |
Why?
|
| Genital Neoplasms, Male | 1 | 2008 | 44 | 0.320 |
Why?
|
| Scrotum | 1 | 2008 | 57 | 0.320 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2021 | 726 | 0.300 |
Why?
|
| Postoperative Care | 1 | 2011 | 739 | 0.300 |
Why?
|
| Suture Techniques | 1 | 2009 | 319 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 2 | 2010 | 602 | 0.290 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 1363 | 0.290 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 622 | 0.260 |
Why?
|
| Lymphatic Metastasis | 9 | 2015 | 4844 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2018 | 10035 | 0.260 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2012 | 2326 | 0.250 |
Why?
|
| Middle Aged | 39 | 2021 | 86204 | 0.240 |
Why?
|
| Predictive Value of Tests | 10 | 2015 | 4892 | 0.240 |
Why?
|
| Urologic Neoplasms | 3 | 2011 | 188 | 0.240 |
Why?
|
| Ureter | 3 | 2010 | 209 | 0.240 |
Why?
|
| Male | 46 | 2021 | 123000 | 0.220 |
Why?
|
| Robotics | 4 | 2012 | 359 | 0.220 |
Why?
|
| Carcinoma | 3 | 2021 | 2578 | 0.210 |
Why?
|
| Aged | 34 | 2021 | 70117 | 0.200 |
Why?
|
| Carcinoma in Situ | 2 | 2018 | 487 | 0.200 |
Why?
|
| Erectile Dysfunction | 2 | 2015 | 212 | 0.180 |
Why?
|
| Nephroureterectomy | 1 | 2019 | 39 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 8 | 2018 | 3981 | 0.170 |
Why?
|
| Humans | 53 | 2021 | 261506 | 0.170 |
Why?
|
| Drug Carriers | 1 | 2020 | 327 | 0.170 |
Why?
|
| Biopsy | 6 | 2014 | 3443 | 0.160 |
Why?
|
| Neoplasm Grading | 5 | 2021 | 1742 | 0.150 |
Why?
|
| Neoplasm Staging | 11 | 2018 | 13658 | 0.140 |
Why?
|
| Collagen Type I | 1 | 2016 | 204 | 0.140 |
Why?
|
| Retrospective Studies | 19 | 2016 | 37905 | 0.130 |
Why?
|
| Cisplatin | 2 | 2015 | 2432 | 0.130 |
Why?
|
| Patient Selection | 4 | 2011 | 2055 | 0.130 |
Why?
|
| Biomarkers, Tumor | 7 | 2016 | 10331 | 0.130 |
Why?
|
| Electrosurgery | 1 | 2014 | 28 | 0.120 |
Why?
|
| Ureteroscopy | 2 | 2011 | 46 | 0.120 |
Why?
|
| Electrocoagulation | 1 | 2014 | 65 | 0.120 |
Why?
|
| Vinblastine | 1 | 2015 | 453 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2012 | 202 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 554 | 0.110 |
Why?
|
| Prognosis | 11 | 2018 | 21713 | 0.110 |
Why?
|
| Pelvis | 2 | 2012 | 362 | 0.110 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 254 | 0.110 |
Why?
|
| Postoperative Complications | 5 | 2011 | 5542 | 0.100 |
Why?
|
| Methotrexate | 1 | 2015 | 999 | 0.100 |
Why?
|
| Adult | 16 | 2020 | 77950 | 0.100 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 29902 | 0.100 |
Why?
|
| New York City | 1 | 2011 | 74 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2016 | 6207 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 205 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 551 | 0.090 |
Why?
|
| ROC Curve | 2 | 2011 | 1183 | 0.090 |
Why?
|
| Hydrogels | 2 | 2021 | 123 | 0.090 |
Why?
|
| Muscle Neoplasms | 1 | 2011 | 109 | 0.090 |
Why?
|
| Kidney Pelvis | 1 | 2010 | 102 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2012 | 4971 | 0.090 |
Why?
|
| Female | 23 | 2021 | 141928 | 0.090 |
Why?
|
| Hypogonadism | 1 | 2013 | 257 | 0.090 |
Why?
|
| Time Factors | 6 | 2020 | 12926 | 0.090 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2009 | 61 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 4975 | 0.080 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2011 | 255 | 0.080 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 4988 | 0.080 |
Why?
|
| Urinary Retention | 1 | 2008 | 21 | 0.080 |
Why?
|
| Diverticulum | 1 | 2008 | 35 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2019 | 12873 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 4298 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2014 | 1529 | 0.080 |
Why?
|
| Testosterone | 1 | 2013 | 619 | 0.080 |
Why?
|
| Schwann Cells | 1 | 2008 | 75 | 0.080 |
Why?
|
| Risk Factors | 8 | 2015 | 17523 | 0.080 |
Why?
|
| Urinary Incontinence | 1 | 2008 | 149 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2015 | 3005 | 0.080 |
Why?
|
| Brazil | 1 | 2008 | 165 | 0.080 |
Why?
|
| Watchful Waiting | 1 | 2009 | 289 | 0.080 |
Why?
|
| Treatment Outcome | 10 | 2020 | 32848 | 0.070 |
Why?
|
| Postoperative Period | 1 | 2009 | 665 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 534 | 0.070 |
Why?
|
| Mass Screening | 1 | 2015 | 1509 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 6009 | 0.070 |
Why?
|
| Abdominal Wall | 1 | 2009 | 184 | 0.070 |
Why?
|
| Urethra | 2 | 2018 | 144 | 0.070 |
Why?
|
| Disease-Free Survival | 5 | 2019 | 10001 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 2864 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2015 | 14889 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2013 | 980 | 0.060 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2009 | 489 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 1656 | 0.060 |
Why?
|
| Catheter Ablation | 1 | 2009 | 620 | 0.060 |
Why?
|
| Disease Progression | 4 | 2018 | 6682 | 0.060 |
Why?
|
| United States | 3 | 2020 | 15433 | 0.050 |
Why?
|
| BCG Vaccine | 2 | 2018 | 399 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 2195 | 0.050 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 14289 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2012 | 4078 | 0.050 |
Why?
|
| Israel | 1 | 2020 | 53 | 0.050 |
Why?
|
| Drug Compounding | 1 | 2020 | 70 | 0.050 |
Why?
|
| Survival Analysis | 4 | 2015 | 9180 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2008 | 1423 | 0.040 |
Why?
|
| Cystoscopy | 1 | 2018 | 88 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 162 | 0.040 |
Why?
|
| Linear Models | 2 | 2013 | 1085 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 15862 | 0.040 |
Why?
|
| Second Harmonic Generation Microscopy | 1 | 2016 | 7 | 0.040 |
Why?
|
| Probability | 2 | 2009 | 866 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2011 | 6869 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 7551 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2009 | 2307 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 7702 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 657 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2010 | 8865 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3472 | 0.030 |
Why?
|
| Survival Rate | 3 | 2011 | 12221 | 0.030 |
Why?
|
| Hematocrit | 1 | 2013 | 142 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 7548 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2009 | 9244 | 0.030 |
Why?
|
| Incidence | 2 | 2015 | 5673 | 0.030 |
Why?
|
| Recurrence | 2 | 2010 | 4758 | 0.030 |
Why?
|
| Lipids | 1 | 2015 | 644 | 0.020 |
Why?
|
| Keratins | 1 | 2012 | 330 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 477 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 945 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 2508 | 0.020 |
Why?
|
| Contraindications | 1 | 2010 | 150 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2011 | 344 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2012 | 309 | 0.020 |
Why?
|
| Age Factors | 2 | 2009 | 5377 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 4320 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 649 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 2170 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 1467 | 0.020 |
Why?
|
| Urination | 1 | 2008 | 36 | 0.020 |
Why?
|
| Penile Erection | 1 | 2008 | 86 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2012 | 850 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 287 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 2009 | 188 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2009 | 335 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2010 | 411 | 0.020 |
Why?
|
| Adolescent | 1 | 2008 | 31252 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 666 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 698 | 0.020 |
Why?
|
| Prevalence | 1 | 2015 | 3260 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3890 | 0.020 |
Why?
|
| Child | 1 | 2008 | 29154 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 6150 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2010 | 627 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2008 | 5687 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2010 | 451 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1323 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 6311 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1546 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2008 | 575 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2008 | 703 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 2139 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 1258 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2594 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2008 | 2316 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2009 | 1987 | 0.010 |
Why?
|
| Biomarkers | 1 | 2015 | 5047 | 0.010 |
Why?
|
| Acute Disease | 1 | 2008 | 2422 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 3441 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2011 | 2054 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 1162 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 5112 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 3552 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 8873 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 21445 | 0.010 |
Why?
|